Sort by
Refine Your Search
-
to develop new cybersecurity solutions”, we are looking for a PhD candidate interested in building positive cybersecurity solutions for organisations. In this five-year project, we aim to develop cybersecurity
-
Apply now PhD in organisational cybersecurity: End-users and teams (1.0 fte) For our NWO-funded project “From ‘what went wrong’ to ‘what works well?’ Using Safety 2 principles to develop new
-
role in the Netherlands. However, given its environmental impact, the sector must be decarbonised in line with Dutch climate targets. Achieving this requires the development of innovative, transformative
-
economic role in the Netherlands. However, given its environmental impact, the sector must be decarbonised in line with Dutch climate targets. Achieving this requires the development of innovative
-
interdisciplinary team and explore the complex relationship between behavior and brain health. This project focuses on developing novel measures of brain health by analyzing everyday behavioral patterns. What you
-
, synthetic chemists team up with immunologists from the Leiden University Medical Centre and computational scientists from the TU Delft to develop the next generation of synthetic CAAR cell therapy for serious
-
period of eighteen months and contribute to the overall development of the project. The candidate is expected to carry out at least one research trip to a selected Special Political Mission of interest
-
academic development are top priorities. Our people are committed to expand fundamental knowledge by curiosity and to look beyond the borders of their own discipline; their aim is to benefit science, and to
-
scientists from the TU Delft to develop the next generation of synthetic CAAR cell therapy for serious autoimmune conditions. The project is a shared position between the CBI-department (Leiden University) and
-
on the development of drugs modulating immunometabolism. Immune dysregulation contributes to many human diseases, including cancer, cardiovascular disease, chronic infections, and neurodegeneration. Developing drugs